Biologic Agents and Approaches in the Management of Patients with Lymphoma: A Critical Appraisal (Q36692582)

15 August 2017

1 reference

title

Biologic agents and approaches in the management of patients with lymphoma. A critical appraisal (English)

1 reference

15 August 2017

Biologic Agents and Approaches in the Management of Patients with Lymphoma: A Critical Appraisal (English)

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

7 November 2022

Longo DL

1 reference

15 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1718939

7 November 2022

publication date

1 October 1991

1 reference

full work available at URL

15 August 2017

https://api.elsevier.com/content/article/PII:S0889858818304015?httpAccept=text/xml

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

https://api.elsevier.com/content/article/PII:S0889858818304015?httpAccept=text/plain

7 November 2022

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Hematology / Oncology Clinics of North America

7 November 2022

published in

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

15 August 2017

page(s)

1067-1087

1 reference

Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

The immunogenicity of chimeric antibodies

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

In vivo administration of anti-CD3 prevents malignant progressor tumor growth

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Immunization to a syngeneic sarcoma by a monoclonal auto-anti-idiotypic antibody

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

"Pure" human hematopoietic progenitors: permissive action of basic fibroblast growth factor

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Autologous bone marrow transplantation for patients with poor-prognosis lymphoma

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Early hematopoietic reconstitution after autologous transplantation with blood-derived stem cells in a patient with advanced lymphoma

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Delivery of novel therapeutic agents in tumors: physiological barriers and strategies

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Suppression of the immune response to immunotoxins with anti-CD4 monoclonal antibodies

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy: A southwest oncology group study

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trial

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma.

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets.

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

The determination of an immunologically active dose of interferon-gamma in patients with melanoma

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Mechanisms of lymphocytotoxicity induced by extracorporeal photochemotherapy for cutaneous T cell lymphoma

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non-Hodgkin's lymphoma

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Treatment of Resistant Malignant Lymphoma with Cyclophosphamide, Total Body Irradiation, and Transplantation of Cryopreserved Autologous Marrow

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Adjuvant bacillus Calmette-Guérin therapy in non-Hodgkin's malignant lymphomas: long-term results of a randomized trial in a single institution

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Clinical studies of ABMT in non-Hodgkin's lymphoma.

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Towards an idiotype vaccine against mammary tumors. Induction of an immune response to breast cancer-associated antigens by anti-idiotypic antibodies

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Identification of a ligand for the c-kit proto-oncogene

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver--conditioned medium.

7 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30401-5

7 November 2022

Identifiers

1 reference